A detailed history of Rhumbline Advisers transactions in Sana Biotechnology, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 171,788 shares of SANA stock, worth $415,726. This represents 0.0% of its overall portfolio holdings.

Number of Shares
171,788
Previous 181,903 5.56%
Holding current value
$415,726
Previous $993,000 28.1%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$3.76 - $6.86 $38,032 - $69,388
-10,115 Reduced 5.56%
171,788 $714,000
Q2 2024

Aug 01, 2024

BUY
$5.23 - $10.44 $131,042 - $261,584
25,056 Added 15.97%
181,903 $993,000
Q1 2024

May 09, 2024

BUY
$4.2 - $11.27 $20,424 - $54,806
4,863 Added 3.2%
156,847 $1.57 Million
Q4 2023

Feb 08, 2024

BUY
$2.8 - $4.55 $5,224 - $8,490
1,866 Added 1.24%
151,984 $620,000
Q3 2023

Nov 09, 2023

SELL
$3.77 - $6.23 $10,299 - $17,020
-2,732 Reduced 1.79%
150,118 $580,000
Q2 2023

Aug 08, 2023

BUY
$3.22 - $7.53 $33,030 - $77,242
10,258 Added 7.19%
152,850 $910,000
Q1 2023

May 11, 2023

BUY
$3.11 - $4.92 $13,248 - $20,959
4,260 Added 3.08%
142,592 $466,000
Q4 2022

Feb 14, 2023

BUY
$3.19 - $6.46 $2,456 - $4,974
770 Added 0.56%
138,332 $546,000
Q3 2022

Nov 10, 2022

BUY
$5.58 - $9.04 $42,089 - $68,188
7,543 Added 5.8%
137,562 $825,000
Q2 2022

Aug 11, 2022

BUY
$4.12 - $9.35 $162,010 - $367,670
39,323 Added 43.36%
130,019 $836,000
Q1 2022

May 12, 2022

BUY
$5.24 - $15.58 $28,914 - $85,970
5,518 Added 6.48%
90,696 $749,000
Q4 2021

Feb 10, 2022

BUY
$15.18 - $23.15 $23,210 - $35,396
1,529 Added 1.83%
85,178 $1.32 Million
Q3 2021

Nov 12, 2021

BUY
$16.29 - $25.88 $974,272 - $1.55 Million
59,808 Added 250.86%
83,649 $1.88 Million
Q2 2021

Aug 05, 2021

BUY
$16.65 - $32.14 $47,618 - $91,920
2,860 Added 13.63%
23,841 $469,000
Q1 2021

May 06, 2021

BUY
$23.04 - $43.5 $483,402 - $912,673
20,981 New
20,981 $702,000

Others Institutions Holding SANA

About Sana Biotechnology, Inc.


  • Ticker SANA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 190,232,000
  • Market Cap $460M
  • Description
  • Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others...
More about SANA
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.